Treatment outcomes of Del19/L858R variants in lung cancer patients harboring concurent EGFR mutations
Main Article Content
Abstract
Co-mutations in non-small cell lung cancer (NSCLC) with EGFR mutations are a novel issue. This study evaluates the efficacy of first- and second-generation Tyrosine Kinase Inhibitors (TKIs), including Gefitinib, Erlotinib, and Afatinib, in 57 patients with advanced-stage NSCLC harboring either EGFR Del19 or L858R mutations in combination with other genetic alterations. The results show that the objective response rate (ORR) was not significantly different between the two groups (p = 0.820), and progression-free survival (PFS) was also comparable between the Del19 and L858R groups (11.22 ± 1.29 months vs. 9.56 ± 0.74 months; p = 0.2378). However, overall survival (OS) in patients with EGFR Del19 co-mutations was significantly longer than in those with EGFR L858R co-mutations (23.08 ± 2.07 months vs. 17.59 ± 1.86 months; p = 0.0183). Thus, while initial treatment outcomes regarding ORR and PFS were similar, patients with EGFR Del19 co-mutations had superior overall survival (OS) compared to those with EGFR L858R co-mutations.
Article Details
Keywords
Non-small cell lung cancer, NSCLC, EGFR-TKIs, EGFR Del19, EGFR L858R, harboring concurrent EGFR mutations
References
2. Hsu WH, Yang JCH, Mok TS, Loong HH. Overview of current systemic management of -mutant NSCLC. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(suppl_1):i3-i9. doi:10.1093/annonc/mdx702
3. Pirker R. What is the best strategy for targeting EGF receptors in non-small-cell lung cancer? Future Oncol Lond Engl. 2015; 11(1): 153-167. doi:10.2217/fon.14.178.
4. Hong W, Wu Q, Zhang J, Zhou Y. Prognostic value of 19-del and 21-L858R mutations in patients with non-small cell lung cancer. Oncol Lett. 2019; 18(4): 3887-3895. doi:10.3892/ol.2019.10715.
5. Liang H, Li C, Zhao Y, et al. Concomitant Mutations in 19Del/L858R Mutation and Their Association with Response to -TKIs in NSCLC Patients. Cancer Manag Res. 2020; 12: 8653-8662. doi:10.2147/CMAR.S255967.
6. Chen LN, Schluger B, Lagos G, et al. Characteristics of patients with -mutant non-small cell lung cancer (NSCLC) at a diverse metropolitan cancer center. J Clin Oncol. 2022; 40(16_suppl): e20593-e20593. doi:10.1200/JCO.2022.40.16_suppl.e20593.
7. Zhang Y, Li S, Lyu Z, et al. The co-mutation of and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients. J Thorac Dis. 2022; 14(1): 185-193. doi:10.21037/jtd-21-1921.
8. Qiu X, Wang Y, Liu F, et al. Survival and prognosis analyses of concurrent mutations in mutant non-small cell lung cancer treated with tyrosine kinase inhibitors. Am J Cancer Res. 2021; 11(6): 3189-3200.
9. Xu J, Zhang X, Yang H, et al. Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive mutations. Oncotarget. 2016; 7(42): 68442-68448. doi:10.18632/oncotarget.12035.
10. Gijtenbeek RGP, Damhuis RAM, van der Wekken AJ, Hendriks LEL, Groen HJM, van Geffen WH. Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study. Lancet Reg Health Eur. 2023; 27: 100592. doi:10.1016/j.lanepe.2023.100592.